NZ529940A - Method of modulating the activity of calcium channels in cardiac cells and reagents therefor - Google Patents

Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

Info

Publication number
NZ529940A
NZ529940A NZ529940A NZ52994002A NZ529940A NZ 529940 A NZ529940 A NZ 529940A NZ 529940 A NZ529940 A NZ 529940A NZ 52994002 A NZ52994002 A NZ 52994002A NZ 529940 A NZ529940 A NZ 529940A
Authority
NZ
New Zealand
Prior art keywords
peptide
seq
cardiac
arg
channel
Prior art date
Application number
NZ529940A
Other languages
English (en)
Inventor
Angela Fay Dulhunty
Marco Giovani Casarotto
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Australian filed Critical Univ Australian
Publication of NZ529940A publication Critical patent/NZ529940A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
NZ529940A 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor NZ529940A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR5066A AUPR506601A0 (en) 2001-05-17 2001-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
PCT/AU2002/000608 WO2002092119A1 (en) 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

Publications (1)

Publication Number Publication Date
NZ529940A true NZ529940A (en) 2006-08-31

Family

ID=3829046

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ529940A NZ529940A (en) 2001-05-17 2002-05-17 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor

Country Status (11)

Country Link
US (1) US20050049198A1 (https=)
EP (1) EP1392344A4 (https=)
JP (1) JP2004535397A (https=)
KR (1) KR20040002970A (https=)
CN (1) CN1516596A (https=)
AU (1) AUPR506601A0 (https=)
BR (1) BR0210902A (https=)
CA (1) CA2446839A1 (https=)
NZ (1) NZ529940A (https=)
WO (1) WO2002092119A1 (https=)
ZA (1) ZA200309727B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5370969B2 (ja) * 2010-02-23 2013-12-18 国立大学法人金沢大学 心筋障害の検査方法
CN101812523B (zh) * 2010-04-09 2012-08-22 广州益善生物技术有限公司 Ryr1基因snp检测特异性引物、液相芯片和检测方法
CN109010799B (zh) * 2018-07-09 2021-07-06 沣潮医药科技（上海）有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
CN109306011B (zh) * 2018-09-27 2021-08-03 中国人民解放军第二军医大学 靶向RyR2蛋白的胞内纳米抗体在制备抗心力衰竭药物中的用途
CN119876003B (zh) * 2025-01-21 2026-04-24 深圳大学 一种肌质网钙泵囊泡的分离纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
DE4110785A1 (de) * 1991-04-04 1992-10-08 Bayer Ag Gewebe-spezifische humane neuronale calcium-kanal-subtypen und deren verwendung
AU1890092A (en) * 1991-04-18 1992-11-17 Indiana University Foundation Novel ester derivatives of ryanodine and dehydroryanodine
JP2003510257A (ja) * 1999-09-22 2003-03-18 コグネティックス・インコーポレイテッド カッパ−コノトキシンｐｖｉｉａの使用
GB0005124D0 (en) * 2000-03-03 2000-04-26 Cellpep Sa Maurocalcin,analogues thereof and their therapeutical uses
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome

Also Published As

Publication number Publication date
CN1516596A (zh) 2004-07-28
BR0210902A (pt) 2004-06-08
AUPR506601A0 (en) 2001-06-07
WO2002092119A1 (en) 2002-11-21
JP2004535397A (ja) 2004-11-25
EP1392344A4 (en) 2005-09-21
EP1392344A1 (en) 2004-03-03
ZA200309727B (en) 2005-08-01
US20050049198A1 (en) 2005-03-03
CA2446839A1 (en) 2002-11-21
KR20040002970A (ko) 2004-01-07

Similar Documents

Publication Publication Date Title
Davis et al. Acute cellular actions of thyroid hormone and myocardial function
Giuliani et al. NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype
WO2003028507A2 (en) Adjustable child support structure with accessories
US20090011989A1 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
JPH10327888A (ja) 新規ｇ−タンパク質結合レセプター（ｈｆｇａｎ７２ｘ）
Mela et al. Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5‐hydroxytryptamine release in the mouse neocortex
CA2333857A1 (en) Growth hormone secretagogue related receptors and nucleic acids
Younès et al. Cardiac synthesis, processing, and coronary release of enkephalin-related peptides
Malagon et al. Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5
NZ529940A (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
CN103261415B (zh) 检测生理活性物质的生物测定法
AU2002341938A1 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
WO2000075166A1 (en) Melanin concentrating hormone receptor
US9527889B2 (en) RFamide-related peptides and methods thereof
BR112015005750B1 (pt) Usos de uma proteína isolada
JPH1175870A (ja) 新規なヒトｇ−タンパク質結合レセプター（ｈｃｅｐｔ０９）
AU2002252850A1 (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
Simmons et al. Molecular characterization and functional expression of a substance P receptor from the sympathetic ganglion of Rana catesbeiana
Piao et al. Amylin-induced suppression of ANP secretion through receptors for CGRP1 and salmon calcitonin
Speed The role of insulin signaling on dopamine transporter trafficking
JP2003507392A (ja) 高血圧症を含む、ヒトの疾患を診断及び治療する方法
Muretta Regulated traffic of Glut4
US20070087326A1 (en) Method of measuring the biological activity of an urotensin II receptor
Jesmin et al. The calcium channel antagonist benidipine reduces plasma and cardiac endothelin-1 levels in type II diabetic rat model
WO2007127809A2 (en) P8 modulation to control hypertension

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed